American Journal of Clinical Dermatology

, Volume 6, Issue 1, pp 49–59 | Cite as

Use of Etanercept in the Dermatology Setting

A Review
  • Mark G. Lebwohl
Review Article


As psoriasis and psoriatic arthritis are chronic in nature, ideal treatment should have sustained efficacy, with minimal short- and long-term toxicities to allow lifelong treatment. Traditional therapies used for psoriatic arthritis or psoriasis, including phototherapies and systemic agents, do not satisfy these criteria. Ninety percent of patients surveyed in 1998 by The National Psoriasis Foundation were not satisfied with their treatment options.

Several observations have supported the introduction of the tumor necrosis factor (TNF) antagonist etanercept as a treatment for psoriatic disease, including the failure of traditional therapies to meet patient needs, evidence that TNF plays a fundamental role in the inflammatory processes underlying psoriatic arthritis and psoriasis, and the safety and efficacy of this agent in other inflammatory, immune-mediated diseases, such as rheumatoid arthritis (RA). Etanercept prevents initiation of the proinflammatory cascade by competitively binding TNF. First indicated for RA, etanercept is also approved for the treatment of psoriatic arthritis, juvenile RA, ankylosing spondylitis, and most recently psoriasis.

Etanercept provides dermatologists with a safe, effective, and convenient treatment option for patients with psoriatic arthritis and psoriasis, which can be used continuously with or without traditional therapies. The self-administered injections provide a distinct advantage over traditional therapies that often require frequent office visits and laboratory monitoring, and other biologic agents that require administration in the doctor’s office. Dermatologists should be aware of the ongoing research with etanercept in psoriasis and other dermatologic conditions.


Psoriasis Infliximab Etanercept Adalimumab Psoriatic Arthritis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The author is a consultant and investigator for Amgen; Abbott Laboratories; Genentech Inc.; Centocor Inc.; and Biogen Inc. Preparation of this manuscript was funded by Amgen.


  1. 1.
    National Psoriasis Foundation. Facts overview. Available from URL: [Accessed 2003 Dee 15]
  2. 2.
    National Psoriasis Foundation. Facts: psoriatic arthritis. Available from URL: [Accessed 2003 Dee 15]
  3. 3.
    Boumpas DT, Illei GG, Tassiulas I. Psoriatic arthritis. In: Klippel JH, Crofford L, Stone JH, et al., editors. Primer on the rheumatic diseases. Atlanta (GA): Arthritis Foundation, 2001: 233Google Scholar
  4. 4.
    Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. J Am Acad Dermatol. 2001; 137: 280–4Google Scholar
  5. 5.
    Lebwohl M, Ali S. Treatment of psoriasis. Part 1: topical therapy and phototherapy. J Am Acad Dermatol. 2001; 45: 487–502PubMedCrossRefGoogle Scholar
  6. 6.
    Therapeutic treatment options. In: Lebwohl MG, Feldman SR, Koo JYM, et al., editors. Psoriasis: treatment options and patient management (handbook of the National Psoriasis Foundation). A product of the Psoriasis Consensus Meeting; 2002 Mar 8-10; Miami Beach (FL). Portland (OR): National Psoriasis Foundation, 2Google Scholar
  7. 7.
    Stern RS, Laird N, Melski J, et al. Cutaneous squamous cell carcinomas in patients treated with PUVA. N Engl J Med. 1984; 310: 1156–61PubMedCrossRefGoogle Scholar
  8. 8.
    Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (Psoralen) and ultraviolet A radiation (PUVA). N Engl J Med. 1997; 336: 1041–5PubMedCrossRefGoogle Scholar
  9. 9.
    Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Eng1J Med. 2003; 349: 658–65CrossRefGoogle Scholar
  10. 10.
    Jeffes III EWB, McCollough JL, Pittlekow MR, et al. Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol. 1995; 104: 183–8PubMedCrossRefGoogle Scholar
  11. 11.
    Saporito FC, Menter MA. Methotrexate and psoriasis in the era of new biologic agents. J Am Acad Dermatol. 2004; 50: 301–9PubMedCrossRefGoogle Scholar
  12. 12.
    Bonifati C, Ameglio F. Cytokines in psoriasis. Int J Dermatol. 1999; 38: 241–51PubMedCrossRefGoogle Scholar
  13. 13.
    Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 2002; 46: 1–23PubMedCrossRefGoogle Scholar
  14. 14.
    Partsch G, Wagner E, Leeb BF, et al. Upregulation of cytokine receptors sTNF-R55, sTNF-R75, and sIL-1R in psoriatic arthritis synovial fluid. J Rheumatol. 1998; 25: 105–10PubMedGoogle Scholar
  15. 15.
    Nickoloff BJ, Karabin GD, Barker K, et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol. 1991; 138: 129–40PubMedGoogle Scholar
  16. 16.
    Terajima S, Higaki M, Igarashi Y, et al. An important role of tumor necrosis factor-alpha in the induction of adhesion molecules in psoriasis. Arch Dermatol Res. 1998; 290: 246–52PubMedCrossRefGoogle Scholar
  17. 17.
    Ettehadi P, Greaves MW, Wallach D, et al. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol. 1994; 96: 146–51PubMedCrossRefGoogle Scholar
  18. 18.
    Ritchlin C, Haas-Smith SA, Hicks D, et al. Patterns of cytokine production in psoriatic synovium. J Rheumatol. 1998; 25: 1544–52PubMedGoogle Scholar
  19. 19.
    Mussi A, Bonifati C, Carducci M, et al. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents. 1997; 11: 115–8PubMedGoogle Scholar
  20. 20.
    Bonifati C, Carducci M, Cordiali Fei P, et al. Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients: relationships with disease severity. Clin Exp Dermatol. 1994; 19: 383–7PubMedCrossRefGoogle Scholar
  21. 21.
    Moreland LW, Schiff MH Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med. 1999; 130: 478–86PubMedGoogle Scholar
  22. 22.
    Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fe fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999; 340: 253–9PubMedCrossRefGoogle Scholar
  23. 23.
    Kremer JM, Weinblatt ME, Bankhurst AD, et al. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. Arthritis Rheum. 2003; 48: 1493–9PubMedCrossRefGoogle Scholar
  24. 24.
    Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002; 46: 1443–50PubMedCrossRefGoogle Scholar
  25. 25.
    Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis: Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000; 342: 763–9PubMedCrossRefGoogle Scholar
  26. 26.
    Lovell DJ, Giannini EH, Reiff A, et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum. 2003; 48: 218–26PubMedCrossRefGoogle Scholar
  27. 27.
    Gorman JD, Sack KE, Davis Jr JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002; 346: 1349–56PubMedCrossRefGoogle Scholar
  28. 28.
    Calin A, Dijkmans BAC, Emery P, et al. A multicentre, placebo-controlled trial of Enbrel in ankylosing spondylitis [abstract]. Ann Rheum Dis. 2003; 62 Suppl. 1: OP0097Google Scholar
  29. 29.
    Davis JC, Van der Heijde D, Braun J. Recombinant human tumor necrosis factor (etanercept) for treating ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum. 2003; 48: 3230–6PubMedCrossRefGoogle Scholar
  30. 30.
    Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet. 2000; 356: 385–90PubMedCrossRefGoogle Scholar
  31. 31.
    Mease PJ, Kivitz A, Burch F, et al. Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (Enbrelf): results of a phase 3 multicenter clinical trial [abstract]. Arthritis Rheum. 2001; 44 Suppl. S90: 226Google Scholar
  32. 32.
    Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004; 50: 2264–72PubMedCrossRefGoogle Scholar
  33. 33.
    Ory P, Sharp IT, Salonen D, et al. Etanercept (Enbrel©) inhibits radiographic progression in patients with psoriatic arthritis [abstract no. OP0089]. Ann Rheum Dis. 2003 Jul; 62 Suppl. 1: 92–3Google Scholar
  34. 34.
    Piquet PF, Gran GE, Vasseli P. Subcutaneous perfusion of tumor necrosis factor induces local proliferation of fibroblasts, capillaries, and epidermal cells, or massive tissue necrosis. Am J Pathol. 1990; 136: 103–10Google Scholar
  35. 35.
    Murloch M, Navaseria H, Balkwell F, et al. Tumor necrosis factor and psoriasis [abstract]. Br J Dermatol. 1989; 119 Suppl. 33; 46Google Scholar
  36. 36.
    Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003; 139: 1627–32PubMedCrossRefGoogle Scholar
  37. 37.
    Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003; 349: 2014–22PubMedCrossRefGoogle Scholar
  38. 38.
    Gottlieb AB, Gordon KB, Wang AT, et al. Withdrawal from etanercept after successful clinical response in psoriasis patients: disease characteristics and the durability of treatment response [abstract]. J Am Acad Dermatol. 2004; 50: P146CrossRefGoogle Scholar
  39. 39.
    Leonardi CL, Elewski BE, Camisa C, et al. The efficacy and safety of etanercept in the retreatment of psoriasis after relapse [abstract]. J Am Acad Dermatol. 2004; 50: P146CrossRefGoogle Scholar
  40. 40.
    Elewski BE, Bob E, Papp K, et al. Efficacy and safety of etanercept inpatients with psoriasis: results of a global phase 3 study [abstract]. J Am Acad Dermatol. 2004; 50: P159CrossRefGoogle Scholar
  41. 41.
    Fleischmann R, Iqbal I, Nandeshwar P, et al. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept. Drug Saf. 2002; 25: 173–97PubMedCrossRefGoogle Scholar
  42. 42.
    Ellman MH MacDonald PA, Hayes FA, et al. Etanercept as a treatment for diffuse scleroderma: a pilot study [abstract]. Arthritis Rheum. 2000; 43 Suppl.: S392Google Scholar
  43. 43.
    Aeberli D, Oertle S, Mauron H, et al. Inhibition of the TNF pathway: use of infiiximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med Wkly. 2002; 132: 414–22PubMedGoogle Scholar
  44. 44.
    Kovach BT, Calamia KT, Walsh JS, et al. Treatment of multicentric reticulohistocytosis with etanercept. Arch Dermatol. 2004; 140: 919–21PubMedCrossRefGoogle Scholar
  45. 45.
    Labrecque P, Null M. Cicatricial pemphigoid and therapy with the TNF inhibitor etanercept [abstract]. J Am Acad Dermatol. 2004; 50: P48CrossRefGoogle Scholar
  46. 46.
    Querfeld C, Guitart J, Kuzel J, et al. Successful treatment of recalcitrant, erythroderma-associated pruritus with etanercept. Arch Dermatol. 2004; 140: 1539–40PubMedCrossRefGoogle Scholar
  47. 47.
    Weinberg JM. Successful treatment of recalcitrant palmoplantar psoriasis with etanercept. Cutis. 2003; 72: 396–8PubMedGoogle Scholar
  48. 48.
    Kamarashev J, Lor P, Forster A, et al. Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept. Dermatology. 2002; 205: 213–6PubMedCrossRefGoogle Scholar
  49. 49.
    Cohen DJ. Successful treatment of pyoderma gangrenosum with etanercept [poster]. Academy Meeting of the American Academy of Dermatology; 2004 Jul 28–Aug 1; New YorkGoogle Scholar
  50. 50.
    Khanna D, Liebling MR, Louie JS. Etanercept ameliorates sarcoidosis and skin disease. J Rhematol. 2003; 30: 1864–7Google Scholar
  51. 51.
    Robinson ND, Guitart J. Recalcitrant, recurrent aphthous stomatitis treated with etanercept. Arch Dermatol. 2003; 139: 1259–62PubMedCrossRefGoogle Scholar
  52. 52.
    Jurgensmeyer JC. Clinical improvement of refractory hidradenitis with etanercept [abstract]. J Am Acad Dermatol. 2004; 50: P15CrossRefGoogle Scholar
  53. 53.
    Enbrel [package insert]. Thousand Oaks (CA): Amgen, 2004Google Scholar
  54. 54.
    Sabath DR, Homan J, Wallis WJ, et al. Serious infection reports with etanercept (ENBREL©) [abstract]. Ann Rheum Dis. 2002; 61 Suppl. 1: OP0099Google Scholar
  55. 55.
    Shakoor N, Michalska M, Harris CA, et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 2002; 359: 579–80PubMedCrossRefGoogle Scholar
  56. 56.
    Humim [package insert]. Abbott Park (IL): Abbott Laboratories, 2004Google Scholar
  57. 57.
    Remicade [package insert]. Malvern (PA): Centocor Inc., 2003Google Scholar
  58. 58.
    Mohan AK, Coté TR, Block JA, et al. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis. 2004; 39: 295–9PubMedCrossRefGoogle Scholar
  59. 59.
    Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999; 41: 401–7PubMedCrossRefGoogle Scholar
  60. 60.
    Keystone E, Schiff M, Kremer J, et al. Once weekly administration of 50mg etanercept (ENBREL©): a phase 3 clinical trial [abstract]. Arthritis Rheum. 2003; 48 Suppl. S653: 1707Google Scholar
  61. 61.
    Moreland LW, Cohen SB, Baumgartner SW, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol. 2001; 28: 1238–44PubMedGoogle Scholar
  62. 62.
    Javitz HS, Ward MM, Farber E, et al. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol. 2002; 46: 850–60PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Mark G. Lebwohl
    • 1
  1. 1.Mount Sinai Medical CenterNew YorkUSA

Personalised recommendations